Cranmer LD, et al. - Given the proposal of chemotherapy as an adjunct to primary local therapy in esthesioneuroblastoma (ENB)/olfactory neuroblastoma (ON), researchers sought to appraise its role in ENB treatment. Investigating the SEER database, they identified ENB/ON (International Classification of Diseases-3 9522). Outcome analysis revealed no improvement in either disease-specific survival (DSS) or overall survival (OS) in correlation to providing chemotherapy in primary ENB/ON treatment, after controlling for known ENB prognostic factors available from SEER. Outcomes other than DSS or OS could be beneficially affected using chemotherapy. Although the concerns regarding chemotherapy treatment misclassification in SEER have been expressed, their analyses did not recognize such misclassification as an explanation for these findings.